Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location |
|---|---|---|---|
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase4 | United States Turkey Lebanon Belgium Colombia Germany Spain Oman Italy France Brazil View All |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase3 | United States Spain Germany Australia Japan Denmark Belgium Canada Finland United Kingdom Italy Norway France Israel Singapore Taiwan Austria View All |
A 24-week rPMS Study in Real-world Setting for Enerzair |
Asthma | Korea, Republic of | |
Asciminib RMP Study |
Chronic Myeloid Leukemia | Korea, Republic of | |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | United States Spain Germany France Czechia Argentina Denmark Portugal Italy Mexico Canada Russian Federation United Kingdom Brazil Turkey Romania Bulgaria Poland Austria View All |
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study |
Relapsing Multiple Sclerosis | Portugal | |
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis |
Multiple Sclerosis | Phase3 | Serbia Ukraine United Kingdom Spain France United States View All |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
IC-MPGN | Phase3 | United States Turkey Spain Italy United Kingdom Brazil Germany Switzerland Argentina Japan Israel Vietnam France Canada India Poland Czechia View All |
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) |
Spinal Muscular Atrophy (SMA) | United States Russian Federation Japan Portugal Ireland Greece Taiwan Korea, Republic of Israel View All |
|
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting |
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation | Spain Italy |